Title: Mediating Role of Chiro-inositol Metabolites on the Effects of HLA-DR-expressing
CD14+ Monocytes in Inflammatory Bowel Disease
Version: 1 Date: 18 Apr 2024
Reviewer's report:
In this manuscript, the authors reported the “CD14+ monocytes indirectly reduce the risk of IBD
occurrence by increasing the levels of Chiro-inositol metabolites, providing a new perspective
on the immunoregulatory mechanisms underlying IBD. ” The structure of the paper is relatively
reasonable and informative. But there are still some aspects which need to be modified.With
these considerations, I recommend its acceptance after introducing corrections.
My comments for the current manuscript are listed as follow:
1. The introduction contains some trivial statements. The introduction should be concise.
2. The tenses in the text are inconsistent. The first paragraph is in the present tense, the second
is in the past tense, and the fourth is in the present tense.
For example: “ Inflammatory bowel disease (IBD), a chronic inflammatory 10 condition, is
caused by several factors involving aberrant immune responses. The two-sample MR approach
was used to estimate the causal relationship of immune cells to IBD. Our findings reveal a new
pathway by which HLA-DR-expressing CD14+ monocytes indirectly reduce the risk of IBD
occurrence by increasing the levels of Chiro-inositol metabolites, providing a new perspective
on the immunoregulatory mechanisms underlying IBD.”
Please check articles for similar problems.
3. The sentence translation in the text is not very accurate.
For example: “The two-sample MR approach was used to estimate the causal relationship of
immune cells to IBD.”
Do you want to show the effect of immune cells on IBD? Or do you want to show the interaction
between immune cells and IBD?
4. The level of translation needs to be further improved.
For example: The research focus has recently shifted towards the role of immune cells in
the development of IBD, highlighting their dual role in initiating and mitigating intestinal
Inflammation.
5. “The data included IBD cases evaluated through imaging, endoscopy, and pathological
assessments to ensure compliance with clinical diagnostic criteria.”
Please specify the specific clinical diagnostic criteria for IBD.
6. Some documents are very old, please change the documents to those of the last 5 years.
7. Some papers or reviews about inflammatory bowel disease should be cited (e.g.,
Acta Biomaterialia, 2023, 160: 252-264; Advanced Science, 2024: 2308092; Journal of
Nanobiotechnology, 2024, 22(1), DOI: org/10.1186/s12951-023-02246-x; Acta Biomaterialia,
2024, 177: 347-360; Materials & Design, 2022, 218: 110686).
8. The author only described the relationship among HLA-DR-expressing CD14+ monocyte,
Chiro-inositol, metabolites and IBD.  There is no in-depth discussion on the possible mechanism
of Chiro-inositol metabolites mediating IBD risk reduction, and I hope to add that.
Title: Mediating Role of Chiro-inositol Metabolites on the Effects of HLA-DR-expressing
CD14+ Monocytes in Inflammatory Bowel Disease
Version: 1 Date: 18 Apr 2024
Reviewer's report:
In this manuscript, the authors reported the “CD14+ monocytes indirectly reduce the risk of IBD
occurrence by increasing the levels of Chiro-inositol metabolites, providing a new perspective
on the immunoregulatory mechanisms underlying IBD. ” The structure of the paper is relatively
reasonable and informative. But there are still some aspects which need to be modified.With
these considerations, I recommend its acceptance after introducing corrections.
My comments for the current manuscript are listed as follow:
1. The introduction contains some trivial statements. The introduction should be concise.
2. The tenses in the text are inconsistent. The first paragraph is in the present tense, the second
is in the past tense, and the fourth is in the present tense.
For example: “ Inflammatory bowel disease (IBD), a chronic inflammatory 10 condition, is
caused by several factors involving aberrant immune responses. The two-sample MR approach
was used to estimate the causal relationship of immune cells to IBD. Our findings reveal a new
pathway by which HLA-DR-expressing CD14+ monocytes indirectly reduce the risk of IBD
occurrence by increasing the levels of Chiro-inositol metabolites, providing a new perspective
on the immunoregulatory mechanisms underlying IBD.”
Please check articles for similar problems.
3. The sentence translation in the text is not very accurate.
For example: “The two-sample MR approach was used to estimate the causal relationship of
immune cells to IBD.”
Do you want to show the effect of immune cells on IBD? Or do you want to show the interaction
between immune cells and IBD?
4. The level of translation needs to be further improved.
For example: The research focus has recently shifted towards the role of immune cells in
the development of IBD, highlighting their dual role in initiating and mitigating intestinal
Inflammation.
5. “The data included IBD cases evaluated through imaging, endoscopy, and pathological
assessments to ensure compliance with clinical diagnostic criteria.”
Please specify the specific clinical diagnostic criteria for IBD.
6. Some documents are very old, please change the documents to those of the last 5 years.
7. Some papers or reviews about inflammatory bowel disease should be cited (e.g.,
Acta Biomaterialia, 2023, 160: 252-264; Advanced Science, 2024: 2308092; Journal of
Nanobiotechnology, 2024, 22(1), DOI: org/10.1186/s12951-023-02246-x; Acta Biomaterialia,
2024, 177: 347-360; Materials & Design, 2022, 218: 110686).
8. The author only described the relationship among HLA-DR-expressing CD14+ monocyte,
Chiro-inositol, metabolites and IBD.  There is no in-depth discussion on the possible mechanism
of Chiro-inositol metabolites mediating IBD risk reduction, and I hope to add that.
Please review this paper.
user
Title: Mediating Role of Chiro-inositol Metabolites on the Effects of HLA-DR-expressing
CD14+ Monocytes in Inflammatory Bowel Disease
Version: 1 Date: 18 Apr 2024
Reviewer's report:
In this manuscript, the authors reported the “CD14+ monocytes indirectly reduce the risk of IBD
occurrence by increasing the levels of Chiro-inositol metabolites, providing a new perspective
on the immunoregulatory mechanisms underlying IBD. ” The structure of the paper is relatively
reasonable and informative. But there are still some aspects which need to be modified.With
these considerations, I recommend its acceptance after introducing corrections.
My comments for the current manuscript are listed as follow:
1. The introduction contains some trivial statements. The introduction should be concise.
2. The tenses in the text are inconsistent. The first paragraph is in the present tense, the second
is in the past tense, and the fourth is in the present tense.
For example: “ Inflammatory bowel disease (IBD), a chronic inflammatory 10 condition, is
caused by several factors involving aberrant immune responses. The two-sample MR approach
was used to estimate the causal relationship of immune cells to IBD. Our findings reveal a new
pathway by which HLA-DR-expressing CD14+ monocytes indirectly reduce the risk of IBD
occurrence by increasing the levels of Chiro-inositol metabolites, providing a new perspective
on the immunoregulatory mechanisms underlying IBD.”
Please check articles for similar problems.
3. The sentence translation in the text is not very accurate.
For example: “The two-sample MR approach was used to estimate the causal relationship of
immune cells to IBD.”
Do you want to show the effect of immune cells on IBD? Or do you want to show the interaction
between immune cells and IBD?
4. The level of translation needs to be further improved.
For example: The research focus has recently shifted towards the role of immune cells in
the development of IBD, highlighting their dual role in initiating and mitigating intestinal
Inflammation.
5. “The data included IBD cases evaluated through imaging, endoscopy, and pathological
assessments to ensure compliance with clinical diagnostic criteria.”
Please specify the specific clinical diagnostic criteria for IBD.
6. Some documents are very old, please change the documents to those of the last 5 years.
7. Some papers or reviews about inflammatory bowel disease should be cited (e.g.,
Acta Biomaterialia, 2023, 160: 252-264; Advanced Science, 2024: 2308092; Journal of
Nanobiotechnology, 2024, 22(1), DOI: org/10.1186/s12951-023-02246-x; Acta Biomaterialia,
2024, 177: 347-360; Materials & Design, 2022, 218: 110686).
8. The author only described the relationship among HLA-DR-expressing CD14+ monocyte,
Chiro-inositol, metabolites and IBD.  There is no in-depth discussion on the possible mechanism
of Chiro-inositol metabolites mediating IBD risk reduction, and I hope to add that.
assistant